Overview

Tranexamic Acid During Upper GI Endoscopic Resection Procedures

Status:
Not yet recruiting
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
Endoscopic resection of gastrointestinal lesions may prevent cancer. However, resection is associated with adverse events such as bleeding. Tranexamic acid (TXA) is a synthetic derivative of lysine that exerts antifibrinolytic effects and may prevent bleeding. The investigators aim to evaluate the effect of local TXA on preventing intraprocedural and postprocedural bleeding in patients undergoing endoscopic mucosal resection (EMR) of upper gastrointestinal lesions.
Phase:
Phase 4
Details
Lead Sponsor:
Assaf-Harofeh Medical Center
Treatments:
Epinephrine
Tranexamic Acid